SEARCH

SEARCH BY CITATION

References

  • Athale, U.H., Razzouk, B.I., Raimondi, S.C., Tong, X., Behm, F.G., Head, D.R., Srivastava, D.K., Rubnitz, J.E., Bowman, L., Pui, C-H. & Ribeiro R.C. (2001) Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood, 97, 37273732.
  • Binkert, F., Mutter, M. & Schinzel, A. (2002) Impact of prenatal diagnosis on the prevalence of live births with Down syndrome in the eastern half of Switzerland 1980–1996. Swiss Medical Weekly, 132, 478484.
  • Chessells, J.M., Harrison, G., Richards, S.M., Bailey, C.C., Hill, F.G.H., Gibson, B.E. & Hann, I.M. (2001) Down's syndrome and acute lymphoblastic leukemia: clinical features and response to treatment. Archives of Disease in Childhood, 85, 321325.
  • Craze, J.L., Harrison, G., Wheatley, K., Hann, I.M. & Chessells, J.M. (1999) Improved outcome of acute myeloid leukemia in Down's syndrome. Archives of Disease in Childhood, 81, 3237.
  • Creutzig, U., Ritter, J., Vormoor, J., Ludwig, W.D., Niemeyer, C., Reinisch, I., Stollmann-Gibbels, B., Zimmermann, M. & Harbott, J. (1996) Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia, 10, 16771686.
  • Dördelmann, M., Schrappe, M., Reiter, A., Zimmermann, M., Graf, N., Schott, G., Lampert, F., Harbott, J., Niemeyer, C., Ritter, J., Dörffel, W., Nessler, G., Kühl, J. & Riehm, H. (1998) Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin–Frankfurt–Munster Group. Leukemia, 12, 645651.
  • Forestier, E., Johansson, B., Borgström, G., Kerndrup, G., Johansson, J. & Heim, S. (2000) Cytogenetic findings in a population-based series of 787 childhood acute lymphoblastic leukemias from the Nordic countries. European Journal of Haematology, 64, 194200.
  • Forestier, E., Heim, S., Blennow, E., Borgström, E., Holmgren, G., Heinonen, G., Johansson, K., Kerndrup, J., Klarskov Andersen, G., Lundin, M., Nordgren, C., Rosenquist, A., Swolin, R., B. & Johansson, B. (2003) Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. British Journal of Haematology, 121, 566577.
  • Frost, B.M., Gustafsson, G., Larsson, R., Nygren, P. & Lönnerholm, G. (2000) Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? Leukemia, 14, 943944.
  • Gamis, A.S., Woods, W.G., Alonzo, T.A., Buxton, A., Lange, B., Barnard, D.R., Gold, S. & Smith, F.O. (2003) Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukaemia: a report from the Children's Cancer Study Group Study 2891. Journal of Clinical Oncology, 21, 34153422.
  • Goldacre, M.J., Wotton C.J., Seagroatt, V. & Yeates, D. (2004) Cancers and immune related diseases associated with Down's syndrome: a record linkage study. Archives of Disease in Childhood, 89, 10141017.
  • Gustafsson, G., Kreuger, A., Clausen, N., Garwicz, S., Kristinsson, J., Lie, S.O., Moe, P.J., Perkkiö, M., Yssing, M. & Saarinen-Pihkala, U.M. on behalf of NOPHO. (1998) Intensified treatment of acute lymphoblastic childhood leukaemia has improved prognosis, especially in non-high risk patients. The Nordic experience of 2648 patients diagnosed between 1981 and 1996. Acta Paediatrica, 87, 11511161.
  • Gustafsson, G., Schmiegelow, K., Forestier, E., Clausen, N., Glomstein, A., Jonmundsson, G., Mellander, L., Mäkipernaa, A., Nygaard, R. & Saarinen-Pihkala, U.M. (2000) Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high dose methotrexate in the reduction of CNS irradiation. Leukemia, 14, 22672275.
  • Hargrave, D.R., Hann, I.M., Richards, S.M., Hill, F.G., Lilleyman, J.S., Kinsey, S., Bailey, C.C., Chessells, J.M., Mitchell, C. & Eden, O.B. (2001) Progressive reduction in treatment related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). British Journal of Haematology, 112, 293299.
  • Hasle, H. (2001) Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncology, 2, 429436.
  • Hasle, H., Clemmensen, I.H. & Mikkelsen, M. (2000) Risks of leukemia and solid tumours in individuals with Down's syndrome. Lancet, 355, 165169.
  • Hasle, H., Niemeyer, C.M., Chessells, J.M., Baumann, I., Bennett, J.M., Kerndrup, G. & Head, D.R. (2003) A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 17, 277282.
  • Heerema, N.A., Sather, H.N., Sensel, M.G., Lee, M.K., Hutchinson, R.J., Nachman, J.B., Lange, B.J., Steinherz, P.G., Bostrom, B.C., Gaynon, P.S. & Uckun, F.M. (1999) Acute lymphoblastic leukemia (ALL) in children with Down syndrome (DS): a report from the Children's Cancer Group (CCG). American Journal of Human Genetics, 65(suppl.), A 130 (abstract).
  • Khoshnood, B., De Vigan, C., Vodovar, V., Goujard, J. & Goffinet, F. (2004) A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981–2000. BJOG: An International Journal of Obstetrics and Gynaecology, 111, 485490.
  • Kojima S., Sako M., Kato K., Hosoi, G., Sato, T., Ohara, A., Koike, K., Okimoto, Y., Nishimura, S., Akiyama, Y., Yoshikawa, T., Ishii, E., Okamura, J., Yazaki, M., Hayashi, Y., Eguchi, M., Tsukimoto, I. & Ueda, K. (2000) An effective chemotherapeutic regimen for acute myeloid leukaemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia, 14, 786791.
  • Krivit, W. & Good, R.A. (1957) Simultaneous occurrence of mongolism and leukemia. American Journal of Disease in Childhood, 94, 289298.
  • Lange, B. (2000) The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. British Journal of Haematology, 110, 512524.
  • Lange, B.J., Kobrinsky, N., Barnard, D.R., Arthur, D.C., Buckley, J.D., Howells, W.B., Gold, S., Sanders, J., Neudorf, S., Smith, F.O. & Woods, W.G. (1998) Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood, 91, 608615.
  • Larsen, S.O., Hansen, J., Christiansen, M. & Nørgaard-Pedersen, B. (2002) Prenatal diagnosis of Down syndrome in Denmark, 1980–1998, and the prospects for future development. Ugeskrift for Læger, 164, 45324536.
  • Levitt, G.A., Stiller, C.A. & Chessells, J.M. (1990) Prognosis of Down's syndrome with acute leukemia. Archives of Disease in Childhood, 65, 212216.
  • Lie, S.O., Berglund, G., Gustafsson, G., Jonmundsson, G., Siimes, M. & Yssing, M. (1990) High dose Ara-C as a single agent consolidation therapy in childhood acute myelogenous leukemia. Hematology and Blood Transfusion, 33, 215221.
  • Lie, S.O., Jonmundsson, G., Mellander, L., Siimes, M.A., Yssing, M. & Gustafsson, G. (1996) A population based study of 272 children with acute myeloid leukemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. British Journal of Haematology, 94, 8288.
  • Lie, S.O., Abrahamsson, J., Clausen, N., Forestier, E., Hasle, H., Hovi, L., Jonmundsson, G., Mellander, L. & Gustafsson, G. (2003) Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. British Journal of Haematology, 122, 217225.
  • Litz, C.E., Davies, S., Brunning, R.D., Kueck, B., Parkin, J.L., Gajl Peczalska, K.J. & Arthur, D.C. (1995) Acute leukemia and the transient disorder associated with Down syndrome: morphologic, immunophenotypic and cytogenetic manifestations. Leukemia, 9, 14321439.
  • Mitelman, F. (ed.) (1995) ISCN: An International System for Human Cytogenetic Nomenclature. Karger, Basel.
  • Mitelman F., Johansson, B. & Mertens, F. (eds) (2004) Mitelman Database of Chromosome Aberrations in Cancer WWW document. URL. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
  • Pui, C., Raimondi, S.C., Borowitz, M.J., Land, V.J., Behm, F.G., Pullen, J., Hancock, M.L., Shuster, J.J., Steuber, P., Crist, W.M., Civin, C.I. & Carroll, A.J. (1993) Immunophenotypes and karyotypes of leukemic cells in Down syndrome and acute lymphoblastic leukemia. Journal of Clinical Oncology, 11, 13611367.
  • Ragab, A.H., Abdel-Mageed, A., Shuster, J.J., Frankel, L.S., Pullen, J., Van Eys, J., Sullivan, M.P., Boyett, J., Borowitz, M. & Crist, W.M. (1991) Clinical characteristics and outcome in children with acute lymphoblasticleukemia in Down's syndrome. Cancer, 67, 10571063.
  • Ravindranath, Y., Abella, E., Krischer, J.P., Wiley, J., Inoue, S., Harris, M., Chauvenet, A., Alvarado, C.S., Dubowy, R., Ritchey, A.K., Land, V., Steuber, CP. & Weinstein, H. (1992) Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML study 8498. Blood, 80, 22102214.
  • Reinhardt, D., Langebrake, C., Diekamp, S., Baumann-Köhler, M. & Creutzig U. (2004) Transient myeloproliferative syndrome (TMD) and acute myeloid leukaemia (AML) in Down syndrome. Pediatric Blood and Cancer, 43, 378 (abstract).
  • Robison, L.L., Nesbit, Jr M.E., Sather, H.N., Level, C., Shahidi, N., Kennedy, A. & Hammond, D. (1984) Down syndrome and acute leukemia in children: a 10-year retrospective survey from Children's Cancer Study Group. Journal of Pediatrics, 105, 235242.
  • Slordahl, S.H., Smeland, E.B., Holte, H., Gronn, M., Lie, S.O. & Seip, M. (1993) Leukemic blasts with markers of four cell lineages in Down's syndrome («Megakaryoblastic leukemia»). Medical and Pediatric Oncology, 21, 254258.
  • Stiller, C.A. & Eatock, E.M. (1999) Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994. Archives of Disease in Childhood, 81, 202208.
  • Taub, J.W., Matherly, L.H., Stout, M.L., Buck, S.A., Gurney, J.G., Ravindranath, Y. (1996) Enhanced metabolism of 1-B-D-Arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood, 87, 3395–3403.
  • Zipursky, A., Poon, A. & Doyle, J. Leukemia In Down Syndrome. (1992) A review. Pediatric Hematology and Oncology, 9, 139149.
  • Zipursky, A., Thorner, P., De Harven, E., Christensen H. & Doyle J. (1994) Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leukemia Research, 18, 163171.
  • Zubizarreta, P., Felice, M.S., Alfaro, E.,Fraquelli, L., Casak, S., Quinteros, R., Cygler, A., Gallego, M., Perez, L.E. & Sackmann-Muriel, F. (1998) Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy. Leukemia Research, 22, 465472.
  • Zwaan, C.M., Kaspers, G.J.L., Pieters, R., Hählen, K., Janka-Schaub, G.E., Van Zantwijk, C.H., Huismans, D.R., De Vries, E., Rots, M.G., Peters, G.J., Jansen, G., Creutzig, U. & Veerman, A.J.P. (2002) Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood, 99, 245251.